Nocturnal Enuresis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Nocturnal Enuresis Market Outlook

Thelansis’s “Nocturnal Enuresis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Nocturnal Enuresis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Nocturnal Enuresis Overview

Nocturnal enuresis (NE) is a condition where an individual involuntarily loses urine while asleep after the age at which bladder control usually begins. NE can cause distress to both children and their families, and can have an adverse impact on behavior, social life, self-esteem, and emotional well-being. NE is common, especially at school entry age, but will spontaneously resolve in over 50% of children by the time they are 10 years old. The aetiology of NE is multifactorial and involves social, behavioral, genetic, and clinical factors. The most common risk factor is genetic/family history. In twin studies, identical twins showed greater concordance compared with non-identical twins (68% and 36%). If one parent has childhood NE, around 50% of their children are affected, increasing to 75% if both parents are affected ¹. Some genetic loci for NE have been identified. The underlying pathophysiology of NE is understood as a complex combination of reduced nocturnal bladder capacity and nocturnal polyuria with sleep arousal difficulties, resulting in enuresis at different stages of the sleep cycle, not only in deep sleep. Commonly associated comorbidities include constipation, urinary tract infection (UTI), obstructive sleep apnea, and bladder dysfunction. Less common conditions with an observed association with NE include cognitive impairment and/or disordered development, diabetes mellitus, diabetes insipidus, seizures, hyperthyroidism, sickle cell disease, pinworms, obesity, and chronic kidney disease. Desmopressin can be used as first-line treatment if an enuresis alarm is unacceptable or short-term control of symptoms is needed. It can be added to enuresis alarm treatment or used alone. Desmopressin is a long-acting synthetic analogue of the hormone vasopressin with several actions, resulting in increased water reabsorption by the kidney and thus a reduced volume of more concentrated urine.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: